Zobrazeno 1 - 10
of 1 554
pro vyhledávání: '"biopanning"'
Autor:
Eunyoung Kim, Jinho Bang, Ji Hye Sung, Jonghwan Lee, Dae Hwan Shin, Sunghyun Kim, Byoung-Cheol Lee
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2024)
Introduction: TMEM16 family proteins are involved in a variety of functions, including ion transport, phospholipid scrambling, and the regulation of membrane proteins. Among them, TMEM16F has dual functions as a phospholipid scramblase and a nonselec
Externí odkaz:
https://doaj.org/article/3fad2f3045a54169ad2f6ed44ac89426
Publikováno v:
Molecules, Vol 29, Iss 13, p 3002 (2024)
In recent years, phage display technology has become vital in clinical research. It helps create antibodies that can specifically bind to complex antigens, which is crucial for identifying biomarkers and improving diagnostics and treatments. However,
Externí odkaz:
https://doaj.org/article/c43e94da169342548ebd1a21ac6ec078
Publikováno v:
Viruses, Vol 16, Iss 4, p 570 (2024)
Phage display is a versatile method often used in the discovery of peptides that targets disease-related biomarkers. A major advantage of this technology is the ease and cost efficiency of affinity selection, also known as biopanning, to identify nov
Externí odkaz:
https://doaj.org/article/bb9620030b724a6e8e9d43e8463a2e23
Autor:
Hiroyuki Takeda, Tatsuhiko Ozawa, Hiroki Zenke, Yoh Ohnuki, Yuri Umeda, Wei Zhou, Honoka Tomoda, Akihiko Takechi, Kimiyoshi Narita, Takaaki Shimizu, Takuya Miyakawa, Yuji Ito, Tatsuya Sawasaki
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 11 (2023)
The VNAR (Variable New Antigen Receptor) is the smallest single-domain antibody derived from the variable domain of IgNAR of cartilaginous fishes. Despite its biomedical and diagnostic potential, research on VNAR has been limited due to the difficult
Externí odkaz:
https://doaj.org/article/a00f4a3c1cfb4e7bb5f0d140f48f362c
Autor:
Marine Potez, Sebastian Snedal, Chunhua She, Jongmyung Kim, Konrad Thorner, Timothy H. Tran, Maria Cecilia Ramello, Daniel Abate-Daga, James K. C. Liu
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundGlioblastoma (GBM) is both the most common and aggressive type of primary brain tumor, associated with high mortality rates and resistance to conventional therapy. Despite recent advancements in knowledge and molecular profiling, recurrence
Externí odkaz:
https://doaj.org/article/f4cd76f1c69e4462853c1899d2da8d9c
Autor:
Renato Kaylan Alves França, Igor Cabral Studart, Marcus Rafael Lobo Bezerra, Larissa Queiroz Pontes, Antonio Marcos Aires Barbosa, Marcelo Macedo Brigido, Gilvan Pessoa Furtado, Andréa Queiroz Maranhão
Publikováno v:
Viruses, Vol 15, Iss 9, p 1903 (2023)
The search for innovative anti-cancer drugs remains a challenge. Over the past three decades, antibodies have emerged as an essential asset in successful cancer therapy. The major obstacle in developing anti-cancer antibodies is the need for non-immu
Externí odkaz:
https://doaj.org/article/dc2a951e098342098ebb456ae9a22c80
Publikováno v:
Molecules, Vol 28, Iss 14, p 5318 (2023)
The larger size and diversity of phage display peptide libraries enhance the probability of finding clinically valuable ligands. A simple way of increasing the throughput of selection is to mix multiple peptide libraries with different characteristic
Externí odkaz:
https://doaj.org/article/10782ad25ef649aca256e8eddcbf925a
Autor:
KRITIKA DHIAL, MANDEEP SHARMA, SUBHASH VERMA, GEETANJALI SINGH, SANJEEV KUMAR, VIPIN KUMAR GUPTA
Publikováno v:
Indian Journal of Animal Sciences, Vol 92, Iss 12 (2022)
• multocida contain various surface-associated antigens that could be used as a target for both therapeutics as well as diagnostics. The current study was planned to select ligands using Ph.D.-12 phage display library. This library was amplified an
Externí odkaz:
https://doaj.org/article/cf86174bc42f4ddaae007656e7cf0746
Autor:
Bifang He, Bowen Li, Xue Chen, Qianyue Zhang, Chunying Lu, Shanshan Yang, Jinjin Long, Lin Ning, Heng Chen, Jian Huang
Publikováno v:
Frontiers in Microbiology, Vol 13 (2022)
Monoclonal antibody drugs targeting the PD-1/PD-L1 pathway have showed efficacy in the treatment of cancer patients, however, they have many intrinsic limitations and inevitable drawbacks. Peptide inhibitors as alternatives might compensate for the d
Externí odkaz:
https://doaj.org/article/e0edea35a6b4449fafc41215a60ffec6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.